QIAGEN launches unique CALR mutation assay for MPN diagnosis
European launch of the new CE marked ipsogen CALR RGQ PCR Kit to improve MPN diagnosis for leukemia patients in line with latest WHO recommendations and clinical guidelines
HILDEN, Germany, Dec. 1, 2016 – QIAGEN today announced the European launch of a unique CE-IVD marked calreticulin (CALR) mutation assay to aid in establishing the diagnosis of myeloproliferative neoplasms (MPN).
The new ipsogen CALR RGQ PCR Kit (ipsogen CALR assay) is intended for the detection of CALR mutations in genomic DNA from subjects suspected of MPN. It enables identification of the two majors CALR mutations, Type 1 and Type 2, and detects additional mutations in the CALR exon 9 region. The ipsogen CALR assay simplifies CALR testing by covering various relevant mutations in a real-time PCR-based assay to deliver multiple clinical results in less than a working day. The test runs on QIAGEN’s QIAsymphony® and Rotor-Gene® (RGQ) platforms, employing the CE-IVD marked Rotor-Gene Q MDx 5Plex HRM Platform real-time cycler with automated analysis and interpretation using the Rotor Gene AssayManager® software. Maximum throughput flexibility is achieved by DNA sample processing from peripheral blood using either the manual QIAamp® DSP DNA Blood Mini Kit or the fully automated sample processing on the QIAsymphony SP instrument. The new ipsogen CALR RGQ PCR Kit is highly synergistic with the CE-IVD marked ipsogen JAK2 RGQ PCR Kit, QIAGEN’s market leading solution to detect the V617F mutation in the janus kinase 2 (JAK2) gene, as CALR mutations can be detected from the same patient sample.
The ipsogen CALR assay is the latest addition to QIAGEN’s ipsogen portfolio of assays for both common and rare leukemia types. MPN are a group of blood cancers characterized by significant symptoms and complications such as thrombosis (blood clots) and a high risk of transformation into acute leukemia. MPN include polycythemia vera (PV), essential thrombocythemia (ET) and various forms of (primary) myelofibrosis (PMF), and affect nearly 250.000 patients in Europe and 300.000 patients in the US. The combined annual incidence rate for MPN worldwide is roughly 2.5 in every 100.000.
“We are excited to announce the launch of our new ipsogen CALR assay to help improve and facilitate patient diagnosis of MPN. The CALR assay is a very important addition to QIAGEN’s market leading ipsogen portfolio of molecular assays that are advancing treatment standards for patients with blood cancers”, said Dr. Christoph Menzel, Director Global Product Management Personalized Healthcare and Oncology at QIAGEN. “We strongly believe our IVD Sample to Insight® workflows for biomarkers such as CALR and JAK2 will make it easier for hemato-oncologists to follow recommended diagnostic testing algorithms and international guidelines, and further demonstrates QIAGEN’s leadership and commitment to innovation in molecular diagnostics."
The importance of CALR mutations in MPN was first described in December 2013 in two important papers published in the New England Journal of Medicine (Klampfl T. et al. and Nangalia J. et al). In April 2014 QIAGEN obtained the exclusive worldwide license rights to intellectual property covering specific mutant alleles of the CALR gene from the Research Center for Molecular Medicine of the Austrian Academy of Sciences, whose scientists led the team that discovered the presence of CALR mutations in MPN (read press release here). Earlier this year, mutations in CALR were included in addition to JAK2 mutations as a major diagnostic criterion for MPN in the updated WHO_guidelines for the classification of myeloid neoplasms and acute leukemia. Both CALR and JAK2 V617F mutations were recently described in clinical guidelines to have prognostic significance. This emphasizes the outstanding importance of CALR mutations, together with JAK2 mutations, in the diagnosis and prognosis of MPN.
QIAGEN also has an exclusive license to intellectual property rights for the detection of the V617F specific mutation in the JAK2 gene for diagnostic purposes. The Company’s ipsogen product line includes more than 20 assays and is considered the market leading portfolio in hemato-oncology testing.
QIAGEN’s QIAsymphony platform is one of the most widely available platforms for medium throughput molecular testing and provides unrivalled flexibility for processing and analysis of samples in laboratory developed tests or validated and regulated assays. The Company expects more than 1750 units to be placed by the end of 2016. The QIAsymphony-RGQ family benefits from the widest range of CE marked assays in this category, spanning therascreen assays for solid tumors, ipsogen assays for blood cancers, artus assays for infectious diseases, as well as certal assays for food testing and cador assays for veterinary testing.
More information about the ipsogen CALR RGQ PCR Kit and ipsogen portfolio for oncohematology is available here.
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of June 30, 2016, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).